Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response.
COVID-19
booster
cell-mediated response
humoral response
immunophenotype
thymic epithelial tumors (TETs)
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
06
2023
accepted:
15
08
2023
medline:
15
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
Thymic epithelial tumors (TETs) are rare malignancies with heterogeneous clinical manifestations. The high frequency of autoimmune paraneoplastic disorders observed in such patients requires caution when using COVID-19 vaccines. Furthermore, TETs are often associated with severe immunodeficiency, making it difficult to predict vaccine immunization. Therefore, we aimed to evaluate immune response to COVID-19 vaccine in patients with TETs. We conducted a prospective study enrolling patients who underwent the SARS-Cov-2 mRNA full vaccine cycle (two doses plus a booster after 6 months of BNT162b2). All patients were enrolled before receiving 1 At the end of the full vaccine cycle, 27 (61.4%) patients developed humoral and 38 (86.4%) cellular responses (IFN γ release by stimulated cells) and showed an increase in activated TH1 and TH17 cells, particularly significant after the booster dose. The number of B and T lymphocytes at baseline was predictive of humoral and cellular responses, respectively. Patients with no evidence of tumor lesions had a higher probability of achieving a humoral response than those with evidence of the disease. Furthermore, the percentage of patients with immune-related disorders (75%), particularly Good's syndrome (47.7%) and myasthenia gravis (29.5%), did not change over the entire vaccine cycle. Overall, 19 of the 44 enrolled patients (43.2%) had COVID-19 during the observation period; none required hospitalization or oxygen support, and no fatalities were observed. SARS-Cov-2 mRNA vaccine determines the immune responses in patients with TET, particularly after the booster dose, and in patients with no evidence of tumor lesions. Preliminary analysis of B and T lymphocytes may help identify patients who have a lower probability of achieving effective humoral and cellular responses and thus may need passive immunization. The vaccine prevented severe COVID-19 infection and is safe.
Sections du résumé
Background
Thymic epithelial tumors (TETs) are rare malignancies with heterogeneous clinical manifestations. The high frequency of autoimmune paraneoplastic disorders observed in such patients requires caution when using COVID-19 vaccines. Furthermore, TETs are often associated with severe immunodeficiency, making it difficult to predict vaccine immunization. Therefore, we aimed to evaluate immune response to COVID-19 vaccine in patients with TETs.
Methods
We conducted a prospective study enrolling patients who underwent the SARS-Cov-2 mRNA full vaccine cycle (two doses plus a booster after 6 months of BNT162b2). All patients were enrolled before receiving 1
Results
At the end of the full vaccine cycle, 27 (61.4%) patients developed humoral and 38 (86.4%) cellular responses (IFN γ release by stimulated cells) and showed an increase in activated TH1 and TH17 cells, particularly significant after the booster dose. The number of B and T lymphocytes at baseline was predictive of humoral and cellular responses, respectively. Patients with no evidence of tumor lesions had a higher probability of achieving a humoral response than those with evidence of the disease. Furthermore, the percentage of patients with immune-related disorders (75%), particularly Good's syndrome (47.7%) and myasthenia gravis (29.5%), did not change over the entire vaccine cycle. Overall, 19 of the 44 enrolled patients (43.2%) had COVID-19 during the observation period; none required hospitalization or oxygen support, and no fatalities were observed.
Conclusion
SARS-Cov-2 mRNA vaccine determines the immune responses in patients with TET, particularly after the booster dose, and in patients with no evidence of tumor lesions. Preliminary analysis of B and T lymphocytes may help identify patients who have a lower probability of achieving effective humoral and cellular responses and thus may need passive immunization. The vaccine prevented severe COVID-19 infection and is safe.
Identifiants
pubmed: 37705978
doi: 10.3389/fimmu.2023.1233056
pmc: PMC10495582
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233056Informations de copyright
Copyright © 2023 Cernera, Gelzo, De Placido, Ottaviano, Pietroluongo, Raia, Scalia, Tortora, Castaldo, Formisano, Palmieri and Giuliano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Infect Dis. 2021 Nov 2;73(9):e3130-e3132
pubmed: 33035306
Sci Immunol. 2021 Dec 24;6(66):eabl5344
pubmed: 34726470
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
JCI Insight. 2021 Dec 22;6(24):
pubmed: 34935643
Clin Exp Rheumatol. 2022 Dec;40(12):2338-2343
pubmed: 36063118
Ann Thorac Surg. 2005 Jan;79(1):16-20
pubmed: 15620907
Front Immunol. 2021 Jan 19;11:617089
pubmed: 33584709
Microorganisms. 2022 Nov 16;10(11):
pubmed: 36422345
Vaccine. 2022 Nov 15;40(48):6963-6970
pubmed: 36283898
J Thorac Oncol. 2022 Feb;17(2):200-213
pubmed: 34695605
Front Immunol. 2022 Aug 18;13:908453
pubmed: 36059463
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Viruses. 2022 Nov 17;14(11):
pubmed: 36423150
J Transl Med. 2021 Sep 23;19(1):403
pubmed: 34556132
J Thorac Oncol. 2023 Jun 28;:
pubmed: 37390981
Mult Scler Relat Disord. 2023 Feb;70:104494
pubmed: 36603292
Cell Rep Med. 2022 Aug 16;3(8):100716
pubmed: 35952669
Expert Rev Vaccines. 2023 Jan-Dec;22(1):341-365
pubmed: 36920116
J Clin Pathol. 2003 Jan;56(1):12-6
pubmed: 12499426
Cell. 2022 Mar 17;185(6):1041-1051.e6
pubmed: 35202566
JTO Clin Res Rep. 2021 Oct;2(10):100229
pubmed: 34514444
ESMO Open. 2022 Oct;7(5):100587
pubmed: 36156449
Front Immunol. 2023 Mar 24;14:1131604
pubmed: 37033955
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
N Engl J Med. 2016 Dec 29;375(26):2570-2581
pubmed: 28029925
Vaccines (Basel). 2021 Sep 29;9(10):
pubmed: 34696220
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Mediastinum. 2022 Jun 14;7:8
pubmed: 36926294
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
Clin Transl Immunology. 2022 Oct 14;11(10):e1423
pubmed: 36254196
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Front Immunol. 2022 Jul 26;13:944713
pubmed: 35990661
Life Sci. 2020 Nov 15;261:118355
pubmed: 32871183
J Neurol. 2022 Dec;269(12):6185-6192
pubmed: 35879563
Front Immunol. 2022 Jun 01;13:859019
pubmed: 35720318
iScience. 2022 Nov 18;25(11):105455
pubmed: 36320330
Front Immunol. 2022 Oct 31;13:1033804
pubmed: 36389719
Front Public Health. 2023 Mar 23;11:1108546
pubmed: 37033069
Nat Commun. 2022 Aug 22;13(1):4922
pubmed: 35995780
Front Immunol. 2023 Feb 09;14:1123724
pubmed: 36845156
Nat Commun. 2022 Sep 21;13(1):5422
pubmed: 36130936
Clin Transl Immunology. 2022 Jan 11;11(1):e1360
pubmed: 35035955
Eur J Cancer. 2022 May;166:202-207
pubmed: 35306318
J Clin Med. 2022 Jul 25;11(15):
pubmed: 35893398
Vaccines (Basel). 2022 Apr 28;10(5):
pubmed: 35632450
Cells. 2023 May 23;12(11):
pubmed: 37296568
Mediastinum. 2019 Sep;3:
pubmed: 31608320